Follow
Olivia Sirpilla
Olivia Sirpilla
Verified email at mayo.edu
Title
Cited by
Cited by
Year
CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities
LAK Fonkoua, O Sirpilla, R Sakemura, EL Siegler, SS Kenderian
Molecular Therapy-Oncolytics 25, 69-77, 2022
902022
SARS-CoV-2 (COVID-19) structural and evolutionary dynamicome: insights into functional evolution and human genomics
R Gupta, J Charron, CL Stenger, J Painter, H Steward, TW Cook, W Faber, ...
Journal of Biological Chemistry 295 (33), 11742-11753, 2020
552020
Virus-induced genetics revealed by multidimensional precision medicine transcriptional workflow applicable to COVID-19
JW Prokop, R Shankar, R Gupta, ML Leimanis, D Nedveck, K Uhl, B Chen, ...
Physiological genomics 52 (6), 255-268, 2020
202020
Sept8/SEPTIN8 involvement in cellular structure and kidney damage is identified by genetic mapping and a novel human tubule hypoxic model
GR Keele, JW Prokop, H He, K Holl, J Littrell, AW Deal, Y Kim, PB Kyle, ...
Scientific Reports 11 (1), 2071, 2021
132021
SARS-CoV-2-encoded proteome and human genetics: from interaction-based to ribosomal biology impact on disease and risk processes
O Sirpilla, J Bauss, R Gupta, A Underwood, D Qutob, T Freeland, C Bupp, ...
Journal of Proteome Research 19 (11), 4275-4290, 2020
132020
Evolutionary Landscape of SOX Genes to Inform Genotype-to-Phenotype Relationships
A Underwood, DT Rasicci, D Hinds, JT Mitchell, JK Zieba, J Mills, ...
Genes 14 (1), 222, 2023
62023
CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS
RL Sakemura, C Manriquez Roman, P Horvei, EL Siegler, JH Girsch, ...
Blood 143 (3), 258-271, 2024
52024
Chimeric antigen receptor engineering of mesenchymal stromal cells (CAR-MSC) enhance immunosuppression and outcomes in graft versus host disease (GvHD) preclinical models
O Sirpilla, RL Sakemura, M Hefazi, JH Girsch, T Huynh, MJ Cox, ...
Blood 140 (Supplement 1), 1579-1580, 2022
32022
Identification of IL-4 as a Key Regulator of CAR T-Cell exhaustion using Functional Genomics and Correlates of the Zuma-1 clinical trial
CM Stewart, MJ Cox, RL Sakemura, EJ Ogbodo, I Can, ...
Blood 140 (Supplement 1), 4536-4537, 2022
32022
CD19 antigen occupancy on cancer cells with the CD19 monoclonal antibody tafasitamab improves the activation, antitumor efficacy, and safety profile of CART19 cell therapy
RL Sakemura, C Manriquez-Roman, P Horvei, MJ Cox, T Huynh, ...
Blood 140 (Supplement 1), 2362-2364, 2022
32022
IL-4 depletion leads to the improvement of CART cell therapy
C Stewart, MJ Cox, R Sakemura, EJ Ogbodo, I Can, CM Roman, K Yun, ...
Cancer Research 83 (7_Supplement), 1153-1153, 2023
22023
Mesenchymal stromal cells with chimaeric antigen receptors for enhanced immunosuppression
O Sirpilla, RL Sakemura, M Hefazi, TN Huynh, I Can, JH Girsch, ...
Nature Biomedical Engineering, 1-18, 2024
12024
Simultaneous targeting of EphA3 on glioblastoma and tumor microenvironment to overcome resistance to CART cell therapy in brain cancer
EJ Ogbodo, MW Ruff, RL Sakemura, C ManriquezRoman, T Huynh, ...
Cancer Research 83 (7_Supplement), 5017-5017, 2023
12023
Bioengineering mesenchymal stromal cells with chimeric antigen receptors induces superior immunosuppressive efficacy in preclinical graft versus host disease models
O Sirpilla, RL Sakemura, M Hefazi, TN Huynh, JH Girsch, I Can, K Yun, ...
2023 Tandem Meetings| Transplantation & Cellular Therapy Meetings of ASTCT …, 2023
12023
Differential susceptibility to Senescence in CART cells based on Co-Stimulatory Signaling
I Can, RL Sakemura, C Manriquez-Roman, O Sirpilla, CM Stewart, K Yun, ...
Blood 140 (Supplement 1), 8600-8601, 2022
12022
TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma
CM Roman, MJ Cox, R Sakemura, K Yun, MM Adada, EL Siegler, ...
Blood 138, 901, 2021
12021
Tumor-derived microRNA125a induces CART cell apoptosis and failure in B cell malignancies
O Sirpilla, RL Sakemura, I Can, TN Huynh, JH GIrsch, CM Roman, ...
Cancer Research 84 (6_Supplement), 3841-3841, 2024
2024
Frontline ibrutinib-based therapy enhances CART cell functions in patients with CLL: Analysis of the phase 3 randomized clinical trial ECOG-ACRIN E1912
TN Huynh, V Wang, T Shanafelt, EL Siegler, CM Stewart, K Yun, LK Mai, ...
Cancer Research 84 (6_Supplement), 3849-3849, 2024
2024
Immunosuppressive monocytes suppress CART19 functions through modulation of the IL-1 pathway
K Yun, R Sakemura, T Huynh, CM Roman, O Sirpilla, C Stewart, J Girsch, ...
Cancer Research 84 (6_Supplement), 6813-6813, 2024
2024
IL-4 drives CART cell exhaustion in a CD4 independent manner
CM Stewart, EL Siegler, TN Huynh, RL Sakemura, B Kimball, L Mai, ...
Cancer Research 84 (6_Supplement), 37-37, 2024
2024
The system can't perform the operation now. Try again later.
Articles 1–20